PhRMA, BIO Mum On Trump’s Tariffs
Executive Summary
While pressing the US trade representative for stronger IP protection, groups representing the brand biopharma sector remain silent on the Trump administration’s plan to hit China with 25% tariffs.
You may also be interested in...
Generics, OTC AND API Groups Object To Proposed US Tariffs On Goods From China
AAM, CHPA, SOCMA and BPTF agree that proposed 25% tariffs on pharmaceuticals and APIs from China is a bad idea, unless perhaps it’s just a negotiating ploy.
Generics, OTC AND API Groups Object To Proposed US Tariffs On Goods From China
AAM, CHPA, SOCMA and BPTF agree that proposed 25% tariffs on pharmaceuticals and APIs from China is a bad idea, unless perhaps it’s just a negotiating ploy.
Global IP Battle: Drug Pricing, Reimbursement Policies Take Center Stage
USTR's 2018 Special 301 Report moves two countries to Priority Watch List in part because of their pricing policies; AAM says focus should be on government reimbursement rather than extending IP protection.